Metabolic dysfunction-associated fatty liver and antiviral response in chronic hepatitis B: A systematic review and meta-analysis

Figure 4 Forest plots comparing alanine aminotransferase normalization rates between patients with chronic hepatitis B alone and those with chronic hepatitis B and metabolic dysfunction-associated fatty liver disease. A: 24 weeks; B: 48 weeks; C: 96 weeks; D: 24 weeks nucleos(t)ide analogues therapy; E: 24 weeks, interferon-based therapy; F: 48 weeks nucleos(t)ide analogues therapy; G: 48 weeks, interferon-based therapy. Pooled effects are expressed as odds ratios with 95%CIs. MAFLD: Metabolic dysfunction-associated fatty liver disease; CHB: Chronic hepatitis B.